Bangladesh DGHS 2025: dengue (5th edition)
Bangladesh national DGHS, Bangladesh Current
National Guideline for Clinical Management of Dengue, 5th edition
Disease Control Division, Directorate General of Health Services, Bangladesh. 2025
Summary checked against the source: 2026-11
Page numbers are the guideline's own. The adult chapters (3–5) are summarised here; the guideline also has chapters on children, pregnancy and intensive care.
At a glance
- Phases: febrile (2–7 days), critical or leakage phase around defervescence (usually day 4–5, lasting 24–48 h), then convalescence (2–5 days). Settling fever is not recovery. [p. 28–30, 47]
- Haematocrit is the key test. A rise >10% suggests leakage starts, ≥20% means significant leakage, 30% impending shock. A falling Hct with unstable vitals means concealed bleeding. [p. 38, 50]
- NS1 for days 1–5, IgM from day 5. CBC and NS1 at the first visit. [p. 39, 45]
- Home care: about 2.4 L of oral fluid a day (ORS, coconut water, juice, soup, not plain water), paracetamol ≤3 g/day, no NSAIDs or steroids. [p. 47–48]
- Critical-phase fluid quota: maintenance + 5% (50 mL/kg), about 4.6 L over 48 h for a 50 kg adult. Use ideal body weight in obesity. [p. 53–54]
- Shock: crystalloid bolus, then step the rate down 350 → 250 → 150 → 100 → 80 → 40 mL/h. Rising Hct despite fluids: colloid. Falling Hct: blood. [p. 57–58]
- No prophylactic platelets or FFP. Fresh whole blood or packed cells for bleeding. [p. 62]
Clinical course
| Phase | Features |
|---|---|
| Febrile (2–7 days) | High continuous fever (39–40 °C), headache, retro-orbital pain, myalgia, arthralgia ("break-bone fever"), flushing. WBC <5000, platelets <150 000. Tender liver and high transaminases suggest DHF is coming |
| Critical / leakage | Starts with defervescence. Platelets <100 000 is an early sign. Hct rises, urine output falls, pleural effusion and ascites. Leak peaks around 24 h and stops by 48 h |
| Equilibrium (some patients) | Leak and reabsorption balance; urine output marginal (0.5–1 mL/kg/h), Hct fluctuates. Keep monitoring |
| Convalescent (2–5 days) | Well-being, appetite, "isles of white in a sea of red" rash, itching of palms and soles, bradycardia, diuresis, Hct at or below baseline, platelets rise. Watch for fluid overload: rising respiratory rate is the earliest sign |
Adapted from BD-DGHS 2025 sections 3.1.2.3–3.1.2.4 [p. 28–35, 52]
Warning signs
- Severe continuous abdominal pain or tenderness
- Persistent vomiting (≥3 in 1 h or ≥4 in 6 h)
- Clinical fluid accumulation (pleural effusion, ascites)
- Mucosal bleeding
- Altered mental state (GCS <15)
- Hepatomegaly ≥2 cm
- Progressive rise in Hct (two readings 6 h apart)
Adapted from BD-DGHS 2025 [p. 28], citing CDC 2024
Classification
| Category | Criteria |
|---|---|
| Dengue fever | Fever 2–7 days, headache, myalgia, arthralgia, rash, mild bleeding, WBC ≤5000, platelets ≤150 000, Hct rise 5–10% |
| DHF | Fever, bleeding tendency (positive tourniquet test, petechiae, mucosal bleeding), platelets ≤100 000, plasma leakage: Hct rise ≥20%, effusion, ascites, albumin <3.5 g/dL, pericholecystic fluid |
| DSS | DHF plus circulatory failure: cold clammy skin, CRT >2 s, tachycardia, weak pulse, pulse pressure ≤20 mm Hg, hypotension |
| Expanded dengue syndrome | Severe organ involvement (liver, kidney, heart, brain, marrow) without plasma leakage |
Adapted from BD-DGHS 2025 [p. 35–36]
The 2025 case-definition chapter also uses the WHO 2009 severity scale: dengue without warning signs, with warning signs, and severe dengue (shock or respiratory distress from leakage, severe bleeding, or severe organ involvement such as AST or ALT ≥1000 IU/L). [p. 45]
Shock
| Compensated | Decompensated (hypotensive) | |
|---|---|---|
| Consciousness | Clear (may be restless) | Restless, lethargic |
| CRT | >2 s | Very prolonged |
| Extremities | Cold | Cold, clammy, mottled |
| Pulse | Weak, thready, tachycardia | Feeble or absent |
| BP | Normal systolic, raised diastolic: pulse pressure ≤20 mm Hg | SBP <90, or a fall >20%, or MAP <60; profound shock: unrecordable |
| Breathing | Tachypnoea | Kussmaul breathing |
| Urine | Reduced | Oliguria or anuria |
Adapted from BD-DGHS 2025 Table 1 [p. 34]
Shock lasting more than 4 hours can cause liver failure; dengue-associated acute liver failure carries about 50% mortality. [Level 5 · p. 30, 33]
Bedside tests
- Tourniquet test: inflate the cuff midway between systolic and diastolic for 5 minutes; ≥10 petechiae per square inch is positive. Only marginally useful on its own. [Level 1 · p. 31]
- Capillary refill time: >2 s means poor perfusion. [Level 6 · p. 32]
Investigations
| Test | Use |
|---|---|
| CBC | WBC ≤5000 and lymphocytes > neutrophils predict leakage. Platelets <100 000 usually precede leakage |
| Haematocrit | Most important monitoring tool. Assume a baseline of 35% (child), 38% (woman), 40% (man) if unknown. Twice daily during leakage; 3-hourly or more in shock |
| NS1 antigen | Positive from day 1; may turn negative by day 4–5 |
| IgM | From day 5, peaks after day 7, lasts 1–3 months. Secondary infection: high IgG in week 2 |
| RT-PCR | Confirms infection within the first 5 days |
| AST > ALT | 2–5 × normal in DF; 5–15 × in DHF. AST ≥1000 = severe organ involvement |
| Albumin | <3.5 g/dL suggests leakage |
Adapted from BD-DGHS 2025 sections 4.1.1–4.1.5 [p. 38–41]
Point-of-care ultrasound
| Finding | Time since leaking began |
|---|---|
| Gallbladder wall thickening alone | Not started yet; rescan in 3–6 h |
| Pericholecystic fluid | Earliest sign of leakage |
| Fluid in Morison's pouch | >6 h |
| Morison's pouch + right pleural effusion | >12 h |
| + left pleural effusion (bilateral effusions and ascites) | >24 h: late critical phase |
Adapted from BD-DGHS 2025 Table 3 [p. 43]
Outpatient care
Admit if there are warning signs, abnormal vital signs or reduced urine output, falling WBC with platelets ≤100 000, or a rising Hct. Consider admitting high-risk patients even without these: pregnancy, age <1 or >65, obesity, diabetes, hypertension, CKD, liver disease, IHD, haemoglobinopathy, peptic ulcer, anticoagulants or steroids, or poor social circumstances. [Table 7 · p. 46–47]
Home management [p. 47–48]
- Rest, preferably under a mosquito net. Tepid sponging.
- Paracetamol, max 3 g/day (60 mg/kg/day in children). It may not fully control the fever.
- Oral fluid about 2400 mL/24 h (2 mL/kg/h if under 50 kg), as ORS, coconut water, juice or soup rather than plain water. Pass urine every 3–4 h.
- Avoid red or brown foods that could be mistaken for blood.
- No NSAIDs (including COX-2 inhibitors) or steroids. Withhold aspirin, clopidogrel, dipyridamole and warfarin where safe.
- CBC daily, the first by day 3 of illness, until afebrile for 24–48 h.
Return at once for clinical deterioration as the fever settles, inability to drink, severe abdominal pain, lethargy or restlessness, bleeding, no urine for 4–6 h, cold extremities or breathlessness. [p. 48]
Inpatient fluid management
Febrile phase
- Oral fluids if the patient can drink. IV only for vomiting, diarrhoea or dehydration. [p. 50, 53]
- 0.9% saline or Hartmann's; total oral + IV about 2400 mL/24 h for an average adult (2 mL/kg/h up to 50 kg). [p. 53]
- Monitor vital signs and urine output 4-hourly, CBC twice daily once platelets are below 100 000.
Critical phase: the fluid quota
Total for the whole critical phase = maintenance + 5% deficit (50 mL/kg). Many patients need less; some in shock need more.
| Calculation for a 50 kg adult | |
|---|---|
| Maintenance (Holliday–Segar) | 100 mL/kg × first 10 kg + 50 mL/kg × next 10 kg + 20 mL/kg × remaining = 1000 + 500 + 600 = 2100 mL |
| 5% deficit | 50 mL/kg × 50 kg = 2500 mL |
| Quota for 48 h | 4600 mL |
Use ideal body weight for overweight patients (women 45.5 kg, men 50 kg, + 0.91 kg per cm above 152.4 cm), and cap the calculation at 50 kg. Adapted from BD-DGHS 2025 section 5.4.2 [p. 53–55]
- Non-shock leakage: start IV fluid at 40 mL/h; if stable, continue for 48 h with the rest of the quota taken orally. Monitor hourly. [p. 56]
- Crystalloid first line, colloid as rescue. [Level 1 · p. 54]
Shock
flowchart TD
A["Compensated shock<br/>pulse pressure ≤20 mm Hg, BP <90/60,<br/>fainting, postural dizziness"] --> B["Now: Hct, blood sugar, oxygen<br/>IV Hartmann's or NS 500 mL/h for 1 h<br/>Urinary catheter · vitals every 15 min"]
B -->|"Improved (pulse pressure >30)"| C["Reduce IV fluid hourly:<br/>350 → 250 → 150 → 100 → 80 → 40 mL/h<br/>for 24 h; then decide by quota and clinical state"]
B -->|Not improved| D["Check ABCS<br/>(acidosis, bleeding, calcium, sugar)"]
D --> E["Increased Hct,<br/>vital signs worse"]
D --> F["Decreased or normal Hct,<br/>vital signs worse,<br/>overt or concealed bleeding"]
E --> G["Colloid: dextran-40 in NS or 6% HES<br/>500 mL over the next 1 h"]
G --> H["Hct falls >8 points<br/>or clinically worse"]
G --> I["Hct falls <8 points<br/>or clinically better"]
H --> J["Packed cells or fresh whole blood,<br/>1 unit over 1 h"]
J -->|Improved| K
J -->|Not improved| L["Check ABCS again;<br/>plan dialysis or organ support"]
F --> M["Packed cells or fresh whole blood,<br/>1 unit over 1 h"]
M -->|Improved| K["Change colloid or blood back to crystalloid<br/>350 → 250 → 150 → 100 → 80 → 40 mL/h<br/>then KVO, continue 24 h"]
I --> K
Adapted from BD-DGHS 2025 Figure 21, compensated shock [p. 57]
Decompensated or profound shock (Figure 22) follows the same logic but starts with 500 mL NS over 15–30 minutes, Hct, group and cross-match, sugar, oxygen and a catheter. A second 500 mL bolus is given within 15 min if not better, with sodium bicarbonate 1–2 mEq/kg. If improved, change to crystalloid 500 mL/h and step down. Shock with fluid overload: colloid 10 mL/kg over 1 h, then IV furosemide. [Figure 22 · p. 58]
When to use colloid [p. 56]
- Shock not responding to two crystalloid boluses with a rising or still high Hct.
- High Hct while the fluid quota (M + 5%) is nearly used up.
- Shock with fluid overload.
Expected Hct response: 500 mL crystalloid lowers Hct by 1–2 points (a fall >3 suggests bleeding); 500 mL dextran by 8–10 points; 1 unit of blood raises it 3–5 points. Group and cross-match before giving colloid. [p. 56]
Not responding to two boluses? Think of ABCS: Acidosis, Bleeding, Calcium, Sugar. [p. 59]
Fluid overload
- Causes: too much IV fluid, hypotonic fluids, fluid for unrecognised bleeding, FFP and platelet transfusions, continuing IV fluids after the critical phase. [p. 59]
- Not in shock: stop IV fluids. In shock: switch to colloid (dextran-40 10 mL/kg, max 30 mL/kg/day). [p. 59]
- IV furosemide 1 mg/kg once BP is stable, during the dextran infusion. Reduce IV fluid to as little as 1 mL/kg/h. [p. 59–61]
- Pleural or peritoneal tapping only as a last resort: bleeding is the main risk. [p. 61]
Bleeding and other problems
- Suspect concealed bleeding with unstable haemodynamics whatever the Hct, a falling Hct after a fluid bolus, refractory shock after 40–60 mL/kg, or worsening acidosis. [p. 61]
- Treat with fresh packed red cells or fresh whole blood, 1 unit at a time. [p. 62]
- Platelet concentrates and FFP don't help in dengue bleeding and worsen fluid overload. Platelets only for very severe thrombocytopenia before urgent surgery, or on clinical judgement. [p. 62]
- IV calcium gluconate 10% 10 mL over 10 min (repeat 6-hourly for 24 h) for any shock, BP not responding to two boluses, >2 units of blood, or myocarditis. [p. 62]
- Hypoglycaemia: 0.1–0.5 g/kg glucose. Bicarbonate not for pH ≥7.10. Hyperchloraemic acidosis from large saline volumes: switch to Hartmann's. [p. 63]
- Diarrhoea: cholera saline 200–300 mL or ORS 250–500 mL after each stool; no antibiotics or antidiarrhoeals. [p. 59]
- Steroids: evidence inconclusive; used only for encephalopathy and HLH. No antiviral works. [Level 1 · p. 67]
Complications
| Complication | Key points |
|---|---|
| Encephalopathy | Usually hepatic encephalopathy, not encephalitis. CT/MRI to exclude haemorrhage. IV fluid ≤80% of maintenance, head up 30°, mannitol, lactulose, vitamin K, glucose 80–100 mg/dL, consider dexamethasone |
| Myocarditis | Usually self-limiting. Troponin, NT-proBNP, echo. Shouldn't stop adequate fluid therapy; give empirical calcium |
| HLH | Suspect with fever and worsening cytopenias beyond day 6, splenomegaly, ferritin ≥500. HLH-2004: 5 of 8 criteria. Dexamethasone 10 mg/m²/day, IVIG; etoposide as rescue |
Adapted from BD-DGHS 2025 section 5.12 [p. 64–66]
Discharge criteria
- No fever for 24 h without antipyretics
- At least 2 days since recovery from shock
- Improving appetite and general condition
- Hct at baseline (or about 38–40% if baseline unknown)
- No distress from pleural effusion, no ascites
- Platelets >50 000/mm³
Adapted from BD-DGHS 2025 section 5.11 [p. 64]
Clinical pearls
- "Afebrile is dangerous": leakage starts as the fever settles.
- Hct up with platelets down = leakage. Hct down with unstable vitals = bleeding.
- Pulse pressure ≤20 mm Hg is compensated shock even with a normal systolic BP.
- Quota: M + 5%, 4.6 L for 50 kg over 48 h. Step-down: 350, 250, 150, 100, 80, 40.
- ABCS for refractory shock: acidosis, bleeding, calcium, sugar.
- No NSAIDs, no IM injections, no prophylactic platelets.
Classes and levels of evidence
How DGHS 2025 (5th ed) grades its recommendations. Adapted from DGHS 2025 (5th ed) Level of evidence table [p. 13]. Hover over any class or level cited on this page to see what it means.
| Level | Meaning |
|---|---|
| Level 1 | Systematic review or meta-analysis of all relevant RCTs |
| Level 2 | At least one well-designed RCT |
| Level 3 | A well-designed controlled trial without randomisation, a systematic review of a complete body of evidence, or mixed-methods intervention studies |
| Level 4 | Well-designed case-control or cohort studies |
| Level 5 | Systematic reviews of descriptive and qualitative studies |
| Level 6 | A single descriptive or qualitative study, or quality-improvement projects |
| Level 7 | Opinion of authorities, expert committee reports, narrative reviews |
The 2025 national dengue guideline tags some statements with a level of evidence from 1 (strongest) to 7, adapted from Melnyk and Fineout-Overholt (2023). It says itself that not all of its content follows this grading, and most statements carry no level. It doesn't grade the strength of recommendations.